TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Inclusion Criteria

• •Histologically or cytologically confirmed metastatic solid tumor, including but not limited to pancreatic adenocarcinoma, breast cancer, melanoma, renal cell carcinoma (RCC), colorectal adenocarcinoma, non-small cell lung cancer, and others approved by the principal investigator
• •Persistent, recurrent or progressive disease following at least one prior line of systemic therapy and there is no available therapy likely to improve survival
• •Measurable disease with \>= 1 target lesion
• •White blood cells (WBC) \>= 4200/mm\^3
• •Absolute neutrophil count (ANC) \>= 1400/mm\^3
• •Platelets (PLT) \>= 100,000/mm\^3
• •Lymphocytes \>= 700/mm\^3
• •Hemoglobin \>= 10 g/dL
• •Total bilirubin =\< 1.5 X upper limit of normal (ULN) unless history of Gilbert's syndrome documented prior to first-line treatment of cancer and other liver function tests are within normal limits
• •Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =\< 1.2 x ULN unless on anticoagulation medication with stable dosing for at least one month; in addition, patient must be able to stop taking medication for up to a week in order to have percutaneous biopsies of tumor tissue performed
• •Aspartate transaminase (AST) and alanine aminotransferase (ALT) =\< 1.5 x ULN (=\< 5 x ULN for patients with liver involvement)
• •Creatinine =\< ULN or a calculated creatinine clearance of \>= 45 ml/min if creatinine is greater than the ULN
• •Alkaline phosphatase =\< 3 x ULN (=\< 5 x ULN if liver or bone involvement)
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• •Willing and able to provide informed written consent
• •Willing and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-up
• •Estimated life expectancy \>= 84 days (3 months)
• •Willing and able to provide samples for correlative research purposes
• •If female of child-bearing potential, have a negative pregnancy test =\< 14 days prior to registration
• •If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 4 months following the last dose of study drug